Latest Breaking News On - Apelli annual report - Page 6 : comparemela.com

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12.

United kingdomUnited statesJeffrey heierCharles wykoffLissa pavlukCaroline baumalMeredith kayaResearch groupExchange commission onApellis pharmaceuticals incExchange commissionLancet glob healthRetina consultantsEleonora ladGeographic atrophySafety information

Apellis Pharmaceuticals (APLS) Announces Publication of 24-Month Results from Phase 3 Studies of SYFOVRE

Apellis Pharmaceuticals (APLS) Announces Publication of 24-Month Results from Phase 3 Studies of SYFOVRE
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJeffrey heierCaroline baumalLissa pavlukCharles wykoffMeredith kayaExchange commission onResearch groupLancet glob healthExchange commissionApellis pharmaceuticals incApellis pharmaceuticalsRetina consultantsEleonora ladGeographic atrophy

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew bombackMeredith kayaLissa pavlukCaroline baumalNational institute of healthExchange commissionColumbia university irving medical centerApellis pharmaceuticals incEuropean unionAmerican society of nephrologyNational kidney foundation websiteExchange commission onAmerican societyKidney week annualColumbia university irving medical

Apellis Announces Preliminary U S Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

Apellis Announces Preliminary U S Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMeredith kayaMadam townsendLissa pavlukAmerican society of retina specialistsApellis pharmaceuticals incLancet glob healthExchange commissionResearch groupExchange commission onThird quarterMedicare advantageOriginal medicareAmerican societyRetina specialists

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Meredith kayaExchange commissionExchange commission onApellis pharmaceuticals incIncentive planStock incentive planNasdaq listing rulePrivate securities litigation reform actApelli annual report